Literature DB >> 23096939

Population pharmacokinetics of digoxin in elderly patients.

Rong Chen1, Su-lan Zou, Ming-li Wang, Yan Jiang, Hui Xue, Chun-yan Qian, Zong-ling Xia.   

Abstract

This study was aimed at determining the population pharmacokinetics of digoxin and identifying factors that explain pharmacokinetic variability in elderly patients. The data of 142 elderly patients and 448 samples were collected after repetitive oral digoxin. Blood samples were drawn at various times after administration. Population pharmacokinetic analysis was performed using nonlinear mixed effects modelling program (NONMEM). A one-compartment model with first-order absorption and elimination was selected as the base model. The influence of demographic characteristics, biochemical and haematological indices as well as other commonly used co-medications were explored. The typical values with interindividual variability for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 8.9 L h(-1) (43.2 %) and 420 L (65.8 %), respectively. The residual variability was 31.6 %. CL/F decreased significantly with renal function, total body weight, calcium channel blockers or spironolactone co-therapy and symptom with congestive heart failure. The median parameter estimates from a nonparametric bootstrap procedure were comparable and within 5 % of the estimates from NONMEM. These results provide important information for clinicians to optimize digoxin regimens in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23096939     DOI: 10.1007/s13318-012-0107-8

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

Review 1.  Potentially harmful drug-drug interactions in the elderly: a review.

Authors:  Lisa E Hines; John E Murphy
Journal:  Am J Geriatr Pharmacother       Date:  2011-11-11

2.  Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.

Authors:  J R Wade; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1993-04

3.  Population pharmacokinetics of digoxin in Korean patients.

Authors:  N V Nagaraja; Y J Park; S Jeon; C D Sands; H Derendorf
Journal:  Int J Clin Pharmacol Ther       Date:  2000-06       Impact factor: 1.366

4.  Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling.

Authors:  Miho Yukawa; Eiji Yukawa; Fumihiro Suematsu; Takako Takiguchi; Hirohito Ikeda; Hatsumi Aki; Masao Mimemoto
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

5.  Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model.

Authors:  E Yukawa; F Suematu; M Yukawa; M Minemoto; S Ohdo; S Higuchi; Y Goto; T Aoyama
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1).

Authors:  Y Tanigawara; N Okamura; M Hirai; M Yasuhara; K Ueda; N Kioka; T Komano; R Hori
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

7.  Changes in the plasma levels and basic pharmacokinetic parameters of digoxin used in combination with gentamicin, amiodarone and spironolactone.

Authors:  E Krusteva
Journal:  Folia Med (Plovdiv)       Date:  1992

8.  Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations.

Authors:  L A Bauer; J R Horn; H Pettit
Journal:  Ther Drug Monit       Date:  1996-02       Impact factor: 3.681

9.  Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study.

Authors:  Agnes L F Chan; Meng-Ting Wang; Chen-Yi Su; Fu-Hsiung Tsai
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

10.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.

Authors:  Björn Hornestam; Markus Jerling; Mats O Karlsson; Peter Held
Journal:  Eur J Clin Pharmacol       Date:  2003-02-19       Impact factor: 2.953

View more
  5 in total

Review 1.  The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

2.  Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review.

Authors:  Mariam Abdel Jalil; Noura Abdullah; Mervat Alsous; Khawla Abu-Hammour
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-05       Impact factor: 2.441

Review 3.  A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population.

Authors:  Mariam H Abdel Jalil; Noura Abdullah; Mervat M Alsous; Mohammad Saleh; Khawla Abu-Hammour
Journal:  Br J Clin Pharmacol       Date:  2020-04-01       Impact factor: 4.335

4.  Improvement of Adequate Digoxin Dosage: An Application of Machine Learning Approach.

Authors:  Ya-Han Hu; Chun-Tien Tai; Chih-Fong Tsai; Min-Wei Huang
Journal:  J Healthc Eng       Date:  2018-08-19       Impact factor: 2.682

5.  Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients.

Authors:  Toshiaki Komatsu; Mami Morita; Futaba Miyaji; Takayuki Inomata; Junya Ako; Koichiro Atsuda
Journal:  J Pharm Health Care Sci       Date:  2015-09-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.